2. Cowper SE, Su L, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol . 2001;23(5):383-393.
3. US Food and Drug Administration. Information for healthcare professionals: gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). Last updated June 4, 2008. www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm. Accessed July 24, 2008.
4. International Center for Nephrogenic Fibrosing Dermopathy Research. www.icnfdr.org. Accessed July 24, 2008.
5. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial . 2006;19(3):191-194.
6. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol . 2006;18(6):614-617.
7. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med . 2006;145(3):234-235.
8. Miskulin D, Gul A, Rudnick MR, Cowper SE. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. www.uptodate.com/patients/content/topic.do?topicKey=dialysis/48700. Accessed July 24, 2008.
9. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant . 2006;21(4):1104-1108.
10. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol . 2006;17(9):2359-2362.
11. Centers for Disease Control and Prevention. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep . 2007;56(7):137-141.
12. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol . 2007;42(2):139-145.
13. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology . 2007;243(1):148-157.
14. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol . 2007;80(950):73-76.
15. GE Healthcare. Omniscan safety update. http://md.gehealthcare.com/omniscan/safety/index.html. Accessed July 24, 2008.
16. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol . 2007;56(1):27-30.
17. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol . 2007;56(1):21-26.
18. Thomsen H; European Society of Urogenital Radiology. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol . 2007;17(1):70-76.
19. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? MAGMA . 2007;20(2):57-62.
20. Kanal E, Barkovich AJ, Bell C, et al; ACR Blue Ribbon Panel on MR Safety. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188(6):1447-1474.
21. GE Healthcare Paper on Nephrogenic Systemic Fibrosis (March 2007). http://md.gehealthcare.com/omniscan/GE% 20Healthcare%20Paper%20On%20Nephrogenic%20 Systemic%20Fibrosis.pdf. Accessed July 24, 2008.
22. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol . 2007;2(2):264-267.
23. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol . 2001;42(3):339-341.
24. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology . 2007;242(3):647-649.
25. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis . 2005;46(4):763-765.
